Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading ... and will not result in a transaction at this time." The eye care company said full separation remains the goal, according to the ...

Bausch + Lomb's product portfolio, particularly its prescription Dry Eye Disease (DED) offerings, has been a focal point for investors and analysts. The company's newest DED drug, Miebo ...

Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading after ending a sales process without finding a buyer. “Taking Bausch + Lomb private with a third-party buyer was one of several options being ...

Eye Drops for Red Eyes: LUMIFY significantly reduces redness to help reveal your eyes' natural radiance. From the eye care experts at Bausch and Lomb, LUMIFY works in 1 minute and lasts up to 8 ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Royal Bank of Canada from $23.00 to $22.00 in a report released on Wednesday,Benzinga reports. The firm ...

Bausch + Lomb's product portfolio, particularly its prescription Dry Eye Disease (DED) offerings, has been a focal point for investors and analysts. The company's newest DED drug, Miebo, has shown ...

Though most of us experience dry eyes occasionally ... a variety of ophthalmological brands and working for Bausch & Lomb marketing contact lenses, surgical equipment, IOL's and general eyecare ...